COMP <GO>
ZLAB vs MRK // ALTMAN Z-SCORE & DEBT/EQUITY
Zai Lab Limited (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: ZLAB 1
— MRK 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: MRK
LAST: $21.67 (-1.83%) • MKT CAP: $2.43B
balance-sheet
0.52
LAST: $148.36 (-0.78%) • MKT CAP: $366.03B
balance-sheet
5.19
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZLAB VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZLAB | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 58.30% | 74.80% | -16.50 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.33% | 3.42% | -9.75 | MRK | /fcf-yield <GO> |
| Operating Margin | -50.20% | 34.30% | -84.50 | MRK | /operating-margins <GO> |
| Net Profit Margin | -38.40% | 28.10% | -66.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 15.00% | 1.30% | +13.70 | ZLAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 0.52 | 5.19 | -4.67 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.0 | 54.3 | -15.30 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.43B | $366.03B | -$363.60B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZLAB REV | MRK REV | ZLAB GROSS % | MRK GROSS % | ZLAB FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $457.2M | $65.01B | 58.3% | 74.8% | -$158.9M | $12.36B |
| FY 2024 | $397.6M | $64.17B | 63.0% | 76.3% | -$220.5M | $18.10B |
| FY 2023 | $266.7M | $60.12B | — | — | -$198.2M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZLAB // BETA —
MRK // BETA 0.92